Novartis AG
NVS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $52 | $47 | $43 | $44 |
| % Growth | 10.8% | 7.4% | -1.2% | – |
| Cost of Goods Sold | $13 | $12 | $12 | $12 |
| Gross Profit | $39 | $34 | $32 | $32 |
| % Margin | 75.2% | 73.3% | 73.4% | 73.3% |
| R&D Expenses | $10 | $11 | $9 | $9 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $13 | $13 | $12 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $1 | $3 | $1 |
| Operating Expenses | $24 | $24 | $24 | $22 |
| Operating Income | $15 | $10 | $8 | $10 |
| % Margin | 28.1% | 20.9% | 18.3% | 22.9% |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | $14 |
| Pre-Tax Income | $14 | $9 | $7 | $25 |
| Tax Expense | $2 | $1 | $1 | $2 |
| Net Income | $12 | $15 | $7 | $24 |
| % Margin | 23.1% | 31.8% | 16% | 54.6% |
| EPS | 5.92 | 7.15 | 3.19 | 10.71 |
| % Growth | -17.2% | 124.1% | -70.2% | – |
| EPS Diluted | 5.87 | 7.1 | 3.17 | 10.63 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $6 | $8 | $7 | $6 |
| EBITDA | $21 | $18 | $15 | $31 |
| % Margin | 40.1% | 39.1% | 33.8% | 70.3% |